Clinical trials: Gene Mutation
Infection, Wound Healing Problem
Fluid Lavage of Open Wounds (FLOW): Pilot Trial
The purpose of this trial is to investigate whether irrigation solution (soap vs. saline solution), or irrigation pressure (high vs. low) will decrease the rate of infection among patients with open fracture wounds.
- Conditions
- Infection, Wound Healing Problem, Nonunion
- Trial name
- FLOW (NCT01069315)
- Testing
- Type of fluid lavage solution, Type of fluid lavage pressure
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 111 people
- Sponsor
- McMaster University
Breast Cancer
Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
The objective of this non-interventional study (NIS) is to evaluate prevalence of ESR1 mutation after endocrine therapy in the palliative setting, quality of life, tolerability, and safety and to describe treatment detail and…
- Trial name
- ELENI (NCT07563595)
- Testing
- Elacestrant, Standard of care (Investigator Choice)
- Where
- 3 sites in Germany
- Volunteers
- 500 people
- Sponsor
- iOMEDICO AG
Acute Myeloid Leukemia, IDH1 Gene Mutation
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia
Among the most notable cancer genome-wide sequencing discoveries in recent years was the finding of mutation hot-spots in the isocitrate dehydrogenase (IDH) genes in grade II/III astrocytomas and oligodendrogliomas and in…
- Conditions
- Acute Myeloid Leukemia, IDH1 Gene Mutation, IDH2 Gene Mutation
- Trial name
- Euro_IDH_AML (NCT04369287)
- Where
- Italy
- Volunteers
- 654 people
- Sponsor
- Istituto Clinico Humanitas
Solid Tumors Harboring a BRAF V600 Mutation
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
This is a multi-center, open-label, dose finding, Phase Ib dose escalation study to estimate the MTD(s) and/or RP2D(s) for the dual combination of LGX818 and MEK162 and the triple combination of LGX818 and MEK162 and LEE011…
- Trial name
- NCT01543698
- Testing
- LGX818, MEK162, LEE011
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 189 people
- Sponsor
- Pfizer
ESR1 Gene Mutation, Breast Cancer (Locally Advanced or Metastatic)
ESR1 Mutations in Metastatic Hormone Receptor-Positive Breast Cancer in the Greek Population
The goal of this observational study is to assess the prevalence of ESR1 mutations in patients with metastatic hormone receptor-positive/HER2-negative breast cancer in Greece and evaluate the associations of these mutations with…
- Conditions
- ESR1 Gene Mutation, Breast Cancer (Locally Advanced or Metastatic), Hormon Receptor Positive Breast Cancer
- Trial name
- ΗΕ 11ESR1/24 (NCT07899463)
- Where
- Greece
- Volunteers
- 500 people
- Sponsor
- Hellenic Cooperative Oncology Group
Retinitis Pigmentosa
Prospective Natural History Study of Retinitis Pigmentosa
This is natural history study of rods and cones degenerations in patients with Retinitis Pigmentosa (RP) caused by pathogenic mutations in RHO, PDE6a or PDE6b gene mutations.
- Trial name
- PHENOROD2 (NCT04285398)
- Testing
- Ophthalmic examinations, Mobility Test
- Where
- 2 sites in United States, France
- Volunteers
- 82 people
- Sponsor
- SparingVision
Nursing, Evidence-Based Nursing
The Effect of HBM-Based Education on Nursing Students
The purpose of the study is to investigate the effect of HBM-based education on CAM knowledge, attitudes, and health beliefs related to medication use among nursing students through a randomized controlled trial.
- Trial name
- HBM (NCT06262698)
- Testing
- Experiment group, Pre-post test
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Kafkas University
Rotator Cuff Repair, Anterior Cruciate Ligament Reconstruction
Ultrasound-Guided Percutaneous Peripheral Nerve Stimulation: A Department of Defense Funded Multicenter Pilot Study
Postoperative pain is usually treated with opioids that have undesirable and sometimes dangerous side effects (e.g., vomiting and respiratory depression)-and yet over 80% of patients still experience inadequate pain relief.
- Conditions
- Rotator Cuff Repair, Anterior Cruciate Ligament Reconstruction, Ankle Arthrodesis or Arthroplasty, Hallux Valgus Correction
- Trial name
- NCT03481725
- Testing
- ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio)
- Where
- 6 sites in United States
- Volunteers
- 65 people
- Sponsor
- University of California, San Diego
Acute Low Back Pain
Usual Care Vs Choice of Alternative Rx: Low Back Pain
This study compares two approaches to the management of acute low back pain: usual care (standard benefit) vs. the choice of: usual care, chiropractic, acupuncture or massage therapy (expanded benefit).
- Trial name
- NCT00010985
- Testing
- Acupuncture, Chiropractic, massage
- Where
- United States
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Multiple Myeloma
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
To determine the maximum tolerated dose (MTD), if present, and dose schedule of ACY-1215 (ricolinostat) in combination with pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma.
- Trial name
- NCT02189343
- Testing
- ACY-1215 in combination with pomalidomide and dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celgene
Endotracheal Tube Position
Pilot Study for Verifying Endotracheal Tube Repositioning Using Ultrasound
The investigators will compare the response to oral endotracheal tube repositioning as measured by chest x-ray and measured by the air-wave device.
- Trial name
- NCT02407158
- Testing
- SonarMed Airwave Device
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Yale University
Breast Cancer
Dynamic Infrared Thermography as an Alternative to CT Angiography
Dynamic infrared thermography (DIRT) is an imaging method that does not require ionizing radiation or contrast injection. The study evaluates if DIRT can be an alternative to computed tomographic angiography (CTA) in perforator…
- Trial name
- DIRT (NCT02806518)
- Testing
- DIRT
- Where
- Norway
- Volunteers
- 25 people
- Sponsor
- University Hospital of North Norway
Hepatic Vein Thromboses, Hepatic Venous Outflow Obstruction
Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome
Portal vein thrombosis is defined as partial or complete occlusion of the portal vein lumen by the blood clot or its replacement by multiple collateral vessels with the hepato-petal flow, known as 'portal cavernoma'.
- Conditions
- Hepatic Vein Thromboses, Hepatic Venous Outflow Obstruction, Portal Vein Thrombosis, Portal Hypertension, Noncirrhotic
- Trial name
- Liv-Thrombus (NCT05123326)
- Testing
- Rotational thromboelastometry, Genetic tests for Thrombophilia, ELISA tests/ Functional assays
- Where
- India
- Volunteers
- 300 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Myelodysplastic Syndromes, P53 Mutation
Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)
This is a prospective,controlled and multi-institution trial.The aim is to identify if using decitabine and Arsenic Trioxide(ATO) as the therapy of Myelodysplastic Syndrome(MDS) has better relapse free survival and complete…
- Trial name
- NCT03377725
- Testing
- Decitabine, Arsenic Trioxide
- Where
- 3 sites in China
- Sponsor
- Li Junmin
HCC - Hepatocellular Carcinoma, TP53 Gene Mutation
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
This study aims to evaluate the effectiveness and safety of a combination therapy with Fuxinqibai monoclonal antibody, Tislelizumab, and Lenvatinib in patients with advanced, unresectable TP53-mutated hepatocellular carcinoma…
- Conditions
- HCC - Hepatocellular Carcinoma, TP53 Gene Mutation, Unresectable, Resistant Cancer
- Trial name
- NCT07535840
- Testing
- Firsekibart + Tislelizumab + Lenvatinib
- Volunteers
- 25 people
- Sponsor
- Tongji Hospital
Follicular Lymphoma
Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial
This is a Multicenter, Retrospective, Biological study ancillary to FOLL12 trial to evaluate the role of EZH2 aberrations in patient with FL treated with immunochemotherapy.
- Trial name
- FIL_FOLL-BIO (NCT05816850)
- Testing
- EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq
- Where
- 26 sites in Italy
- Volunteers
- 654 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
The purpose of this study is to determine whether GSK1120212, a MEK inhibitor, is an effective and safe treatment for cancer subjects with metastatic uveal melanoma and mutation-positive GNAQ or GNA11 metastatic melanoma.
- Conditions
- GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma, Cancer, Metastatic Uveal Melanoma
- Trial name
- NCT01328106
- Testing
- GSK1120212
- Sponsor
- GlaxoSmithKline
EGFR Positive Non-small Cell Lung Cancer, Brain Metastases
A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases
Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment against first-generation TKIs.
- Trial name
- NCT04643847
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- First People's Hospital of Hangzhou
Radioiodine-refractory Differentiated Thyroid Cancer
A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients
This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R…
- Trial name
- NCT07770074
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
DLBCL, MYD88 Gene Mutation
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
The purpose of this study is to evaluate the efficacy and safety of Ibrutinib Combined With Rituximab in Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies.
- Conditions
- DLBCL, MYD88 Gene Mutation, CD79A Gene Mutation, CD79B Gene Mutation
- Trial name
- NCT04994626
- Testing
- Ibrutinib Combined With Rituximab
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.